Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Samsung Bioepis Co., Ltd. today announced that PYZCHIVA® (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been approved for the treatment ...

MUMBAI:  Biocon Biologics Ltd has announced the US launch of Yesintek  (ustekinumab-kfce), one of the first biosimilars to Janssen's Stelara® to enter the American market. The biosimilar, approved by ...

Biocon shares will be in focus on Tuesday after its subsidiary, Biocon Biologics, announced the launch of YESINTEK ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars ...

Selarsdi is approved by the FDA in several presentations, including 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Indian benchmark indices Nifty 50 and Sensex ended the previous trade session in the red. Nifty 50 closed at 22,552.50, while ...

In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indicationsmatching the reference product Stelara ® (ustekinumab) and has granted a provisional ...